Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Biologics, PDE4 Inhibitors), By Route Of Administration (Topical, Injectable, Oral), By Region, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
Atopic Dermatitis Drugs Market Growth & Trends
The global atopic dermatitis drugs market size is expected to reach USD 27.68 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.0% from 2022 to 2030. The market for atopic dermatitis (AD) drugs is expected to witness growth opportunities owing to factors such as the increasing prevalence of atopic dermatitis across the globe, rising awareness, and high demand for treatment. Furthermore, the ongoing launch of innovative products to capture the market is a key strategy adopted by the players to gain market share and maintain their dominance.
A rising number of products in the pipeline, which are highly effective and show fewer adverse effects, is expected to drive the market. For instance, overall, 11 novel drugs indicated for atopic dermatitis are anticipated to be launched in the global market between 2020 and 2029. These include the following drug classes: Janus Kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4), and interleukin-4 & -13 (IL-4/13). These launches offer improvement in the quality of life and additional choices of treatments to patients with severe and moderate forms of AD.
Support from regulatory authorities, such as the provision of fast-track designation, is anticipated to
impel R&D on AD. For instance, Lebrikizumab by Demira, Inc. received a fast-track designation. Moreover, in October 2020, Forte Biosciences, Inc.’s drug FB-401 was granted the fast-track designation by the FDA. Hence, the growing interest of companies in R&D is expected to propel the growth of the market.
An increase in funding for research and development of novel therapies for atopic dermatitis combined with proactive government initiatives will boost regional growth. Collaborations between public and private associations are expected to increase consumer awareness across the globe. For instance, in June 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) announced the launch of Moizerto ointment (difamilast) for treating AD in Japan. This ointment is a non-steroidal topical phosphodiesterase type-4 inhibitor.
The Japanese Dermatological Association (JDA) provides AD guidelines for AD in Japan. These guidelines were revised in 2020, specifying diagnostic criteria as well as treatments. For instance, inflammation-related AD is treated using topical corticosteroids and tacrolimus. This facilitates the treatment of patients in a systematic manner, thus improving treatment efficacy.
Atopic Dermatitis Drugs Market Report Highlights
Atopic Dermatitis Drugs Market Growth & Trends
The global atopic dermatitis drugs market size is expected to reach USD 27.68 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.0% from 2022 to 2030. The market for atopic dermatitis (AD) drugs is expected to witness growth opportunities owing to factors such as the increasing prevalence of atopic dermatitis across the globe, rising awareness, and high demand for treatment. Furthermore, the ongoing launch of innovative products to capture the market is a key strategy adopted by the players to gain market share and maintain their dominance.
A rising number of products in the pipeline, which are highly effective and show fewer adverse effects, is expected to drive the market. For instance, overall, 11 novel drugs indicated for atopic dermatitis are anticipated to be launched in the global market between 2020 and 2029. These include the following drug classes: Janus Kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4), and interleukin-4 & -13 (IL-4/13). These launches offer improvement in the quality of life and additional choices of treatments to patients with severe and moderate forms of AD.
Support from regulatory authorities, such as the provision of fast-track designation, is anticipated to
impel R&D on AD. For instance, Lebrikizumab by Demira, Inc. received a fast-track designation. Moreover, in October 2020, Forte Biosciences, Inc.’s drug FB-401 was granted the fast-track designation by the FDA. Hence, the growing interest of companies in R&D is expected to propel the growth of the market.
An increase in funding for research and development of novel therapies for atopic dermatitis combined with proactive government initiatives will boost regional growth. Collaborations between public and private associations are expected to increase consumer awareness across the globe. For instance, in June 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) announced the launch of Moizerto ointment (difamilast) for treating AD in Japan. This ointment is a non-steroidal topical phosphodiesterase type-4 inhibitor.
The Japanese Dermatological Association (JDA) provides AD guidelines for AD in Japan. These guidelines were revised in 2020, specifying diagnostic criteria as well as treatments. For instance, inflammation-related AD is treated using topical corticosteroids and tacrolimus. This facilitates the treatment of patients in a systematic manner, thus improving treatment efficacy.
Atopic Dermatitis Drugs Market Report Highlights
- In 2021, biologics dominated the market owing to their higher demand and rising biologics approvals
- The injectable route of administration segment held the largest share in 2021 and is likely to maintain its dominance throughout the forecast period
- Europe is expected to register a significant CAGR in the forecast period owing to factors such as rising awareness among the population about skin conditions such as atopic dermatitis and the presence of a favorable regulatory framework
- North America dominated the market in 2021 due to the presence of leading market players, increased prevalence of atopic dermatitis, and increased research activities within the region
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: commodity flow approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective
1.9.2 Objective
1.9.3 Objective
1.9.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 ATOPIC DERMATITIS DRUGS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.1.1 Increasing prevalence of atopic dermatitis drugs across the globe
3.1.1.2 Availability of robust product portfolio
3.1.2 Market Restraint Analysis
3.1.2.1 Side-effects Associated with drugs and high cost of these therapeutics
3.2 Penetration and Growth Prospect Mapping
3.3 Business Environment Analysis Tools
3.3.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.3.2 Porter’s Five Forces Analysis
3.3.3 Industry Analysis - Ansoff Matrix
3.4 Pricing Analysis
3.5 Regulatory Scenario
CHAPTER 4 REGULATORY & POLITICAL FORCES
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.1.1 Heat map analysis
4.2 Company Categorization
4.2.1 Innovators
4.2.2 Market Leaders
4.3 Vendor Landscape
4.3.1 List of key distributors and channel partners
4.3.2 Key customers
4.3.3 Key company market share analysis, 2021
4.4 Public Companies
4.4.1 Company market position analysis
4.4.3.1 Market Differentiators
4.5 Private Companies
4.5.1 List of key emerging companies
4.6 Major Deals and Strategic Alliances Analysis
4.6.1 New Product Launch
4.6.2 Acquisitions
4.6.3 Expansion
4.6.4 Licensing and Partnerships
CHAPTER 5 ATOPIC DERMATITIS DRUGS MARKET - SEGMENT ANALYSIS, BY DRUG CLASS, 2018 - 2030 (USD MILLION)
5.1 Drug Class Market Share Analysis, 2021 & 2030 (USD Million)
5.2 Segment Dashboard
5.3 Market Size & Forecasts and Trend Analysis, 2018 - 2030 (USD Million)
5.3.1 Corticosteroids
5.3.1.1 Corticosteroids Atopic Dermatitis Drugs market estimates and forecast, 2018 - 2030 (USD Million)
5.3.2 Calcineurin Inhibitors
5.3.2.1 Calcineurin Inhibitors Atopic Dermatitis Drugs market estimates and forecast, 2018 - 2030 (USD Million)
5.3.3 PDE4 Inhibitors
5.3.3.1 PDE4 Inhibitors Atopic Dermatitis Drugs market estimates and forecast, 2018 - 2030 (USD Million)
5.4 Biologics
5.4.4.1 Biologics Atopic Dermatitis Drugs market estimates and forecast, 2018 - 2030 (USD Million)
5.5 Others
5.5.5.1 Others Atopic Dermatitis Drugs market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 6 ATOPIC DERMATITIS DRUGS MARKET - SEGMENT ANALYSIS, BY ROUTE OF ADMINISTRATION, 2018 - 2030 (USD MILLION)
6.1 Route of Administration Market Share Analysis, 2021 & 2030 (USD Million)
6.2 Segment Dashboard
6.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
6.3.1 Topical
6.3.1.1 Topical market estimates and forecast, 2018 - 2030 (USD Million)
6.3.2 Injectable
6.3.2.1 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3 Oral
6.3.3.1 Oral market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 7 ATOPIC DERMATITIS DRUGS MARKET - SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
7.1 Regional Market Share Analysis, 2021 & 2030 (USD Million)
7.2 Regional Market Dashboard
7.3 North America
7.3.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
7.3.2 U.S.
7.3.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
7.4 Canada
7.4.1.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
7.5 Europe
7.5.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
7.5.2 Germany
7.5.2.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
7.5.3 U.K.
7.5.3.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
7.5.4 Spain
7.5.4.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
7.5.5 France
7.5.5.1 France market estimates and forecast, 2018 - 2030 (USD Million)
7.5.6 Italy
7.5.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
7.6 Asia Pacific
7.6.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
7.6.2 Japan
7.6.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
7.6.3 China
7.6.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
7.6.4 India
7.6.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
7.6.5 South Korea
7.6.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
7.6.6 Australia
7.6.6.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
7.7 Latin America
7.7.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
7.7.2 Brazil
7.7.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
7.7.3 Mexico
7.7.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
7.7.4 Argentina
7.7.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
7.8 Middle East & Africa
7.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
7.8.2 South Africa
7.8.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
7.8.3 UAE
7.8.3.1 UAE market estimates and forecast, 2018 - 2030 (USD Million)
7.8.4 Saudi Arabia
7.8.4.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 8 COMPETITIVE & VENDOR LANDSCAPE
8.1 Participant Categorization
8.1.1 Innovators
8.1.2 Market Leaders
8.2 Strategy Mapping
8.2.1 Key Strategies Chosen by Players in this Market include
8.2.1.1 Launch of new products
8.2.1.2 Acquisition
8.2.1.3 Expansion
8.2.1.4 Agreements, collaborations, partnerships
8.2.1.5 Others (realignment, divestment, market penetration)
8.3 Strategic Framework
8.3.1 Key Company Market Share Analysis, 2021
8.4 Company Profiles
8.4.1 Pfizer Inc.
8.4.1.1 Company overview
8.4.1.2 Financial performance
8.4.1.3 Product benchmarking
8.4.1.4 Strategic initiatives
8.4.2 Sanofi
8.4.2.1 Company overview
8.4.2.2 Financial performance
8.4.2.3 Product benchmarking
8.4.2.4 Strategic initiatives
8.4.3 Regeneron Pharmaceuticals Inc.
8.4.3.1 Company overview
8.4.3.2 Financial performance
8.4.3.3 Product benchmarking
8.4.3.4 Strategic initiatives
8.4.4 LEO Pharma Inc
8.4.4.1 Company overview
8.4.4.2 Financial performance
8.4.4.3 Product pipeline
8.4.4.4 Strategic initiatives
8.4.5 Otsuka Pharmaceutical Co., Ltd.
8.4.5.1 Company overview
8.4.5.2 Financial performance
8.4.5.3 Product pipeline
8.4.5.4 Strategic initiatives
8.4.6 AbbVie Inc.
8.4.6.1 Company overview
8.4.6.2 Product benchmarking
8.4.6.3 Strategic initiatives
8.4.7 GALDERMA LABORATORIES, L.P.
8.4.7.1 Company overview
8.4.7.2 Financial performance
8.4.7.3 Product benchmarking
8.4.7.4 Strategic initiatives
8.4.8 Dermira, Inc. (Eli Lilly and Company)
8.4.8.1 Company overview
8.4.8.2 Financial performance
8.4.8.3 Product benchmarking
8.4.8.4 Strategic initiatives
8.4.9 Novartis AG
8.4.9.1 Company overview
8.4.9.2 Financial performance
8.4.9.3 Product benchmarking
8.4.9.4 Strategic initiatives
8.4.10 Incyte Corporation
8.4.10.1 Company overview
8.4.10.2 Financial performance
8.4.10.3 Product benchmarking
8.4.10.4 Strategic initiatives
1.1 Market Segmentation and Scope
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: commodity flow approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective
1.9.2 Objective
1.9.3 Objective
1.9.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 ATOPIC DERMATITIS DRUGS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.1.1 Increasing prevalence of atopic dermatitis drugs across the globe
3.1.1.2 Availability of robust product portfolio
3.1.2 Market Restraint Analysis
3.1.2.1 Side-effects Associated with drugs and high cost of these therapeutics
3.2 Penetration and Growth Prospect Mapping
3.3 Business Environment Analysis Tools
3.3.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.3.2 Porter’s Five Forces Analysis
3.3.3 Industry Analysis - Ansoff Matrix
3.4 Pricing Analysis
3.5 Regulatory Scenario
CHAPTER 4 REGULATORY & POLITICAL FORCES
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.1.1 Heat map analysis
4.2 Company Categorization
4.2.1 Innovators
4.2.2 Market Leaders
4.3 Vendor Landscape
4.3.1 List of key distributors and channel partners
4.3.2 Key customers
4.3.3 Key company market share analysis, 2021
4.4 Public Companies
4.4.1 Company market position analysis
4.4.3.1 Market Differentiators
4.5 Private Companies
4.5.1 List of key emerging companies
4.6 Major Deals and Strategic Alliances Analysis
4.6.1 New Product Launch
4.6.2 Acquisitions
4.6.3 Expansion
4.6.4 Licensing and Partnerships
CHAPTER 5 ATOPIC DERMATITIS DRUGS MARKET - SEGMENT ANALYSIS, BY DRUG CLASS, 2018 - 2030 (USD MILLION)
5.1 Drug Class Market Share Analysis, 2021 & 2030 (USD Million)
5.2 Segment Dashboard
5.3 Market Size & Forecasts and Trend Analysis, 2018 - 2030 (USD Million)
5.3.1 Corticosteroids
5.3.1.1 Corticosteroids Atopic Dermatitis Drugs market estimates and forecast, 2018 - 2030 (USD Million)
5.3.2 Calcineurin Inhibitors
5.3.2.1 Calcineurin Inhibitors Atopic Dermatitis Drugs market estimates and forecast, 2018 - 2030 (USD Million)
5.3.3 PDE4 Inhibitors
5.3.3.1 PDE4 Inhibitors Atopic Dermatitis Drugs market estimates and forecast, 2018 - 2030 (USD Million)
5.4 Biologics
5.4.4.1 Biologics Atopic Dermatitis Drugs market estimates and forecast, 2018 - 2030 (USD Million)
5.5 Others
5.5.5.1 Others Atopic Dermatitis Drugs market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 6 ATOPIC DERMATITIS DRUGS MARKET - SEGMENT ANALYSIS, BY ROUTE OF ADMINISTRATION, 2018 - 2030 (USD MILLION)
6.1 Route of Administration Market Share Analysis, 2021 & 2030 (USD Million)
6.2 Segment Dashboard
6.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
6.3.1 Topical
6.3.1.1 Topical market estimates and forecast, 2018 - 2030 (USD Million)
6.3.2 Injectable
6.3.2.1 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3 Oral
6.3.3.1 Oral market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 7 ATOPIC DERMATITIS DRUGS MARKET - SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
7.1 Regional Market Share Analysis, 2021 & 2030 (USD Million)
7.2 Regional Market Dashboard
7.3 North America
7.3.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
7.3.2 U.S.
7.3.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
7.4 Canada
7.4.1.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
7.5 Europe
7.5.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
7.5.2 Germany
7.5.2.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
7.5.3 U.K.
7.5.3.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
7.5.4 Spain
7.5.4.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
7.5.5 France
7.5.5.1 France market estimates and forecast, 2018 - 2030 (USD Million)
7.5.6 Italy
7.5.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
7.6 Asia Pacific
7.6.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
7.6.2 Japan
7.6.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
7.6.3 China
7.6.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
7.6.4 India
7.6.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
7.6.5 South Korea
7.6.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
7.6.6 Australia
7.6.6.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
7.7 Latin America
7.7.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
7.7.2 Brazil
7.7.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
7.7.3 Mexico
7.7.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
7.7.4 Argentina
7.7.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
7.8 Middle East & Africa
7.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
7.8.2 South Africa
7.8.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
7.8.3 UAE
7.8.3.1 UAE market estimates and forecast, 2018 - 2030 (USD Million)
7.8.4 Saudi Arabia
7.8.4.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 8 COMPETITIVE & VENDOR LANDSCAPE
8.1 Participant Categorization
8.1.1 Innovators
8.1.2 Market Leaders
8.2 Strategy Mapping
8.2.1 Key Strategies Chosen by Players in this Market include
8.2.1.1 Launch of new products
8.2.1.2 Acquisition
8.2.1.3 Expansion
8.2.1.4 Agreements, collaborations, partnerships
8.2.1.5 Others (realignment, divestment, market penetration)
8.3 Strategic Framework
8.3.1 Key Company Market Share Analysis, 2021
8.4 Company Profiles
8.4.1 Pfizer Inc.
8.4.1.1 Company overview
8.4.1.2 Financial performance
8.4.1.3 Product benchmarking
8.4.1.4 Strategic initiatives
8.4.2 Sanofi
8.4.2.1 Company overview
8.4.2.2 Financial performance
8.4.2.3 Product benchmarking
8.4.2.4 Strategic initiatives
8.4.3 Regeneron Pharmaceuticals Inc.
8.4.3.1 Company overview
8.4.3.2 Financial performance
8.4.3.3 Product benchmarking
8.4.3.4 Strategic initiatives
8.4.4 LEO Pharma Inc
8.4.4.1 Company overview
8.4.4.2 Financial performance
8.4.4.3 Product pipeline
8.4.4.4 Strategic initiatives
8.4.5 Otsuka Pharmaceutical Co., Ltd.
8.4.5.1 Company overview
8.4.5.2 Financial performance
8.4.5.3 Product pipeline
8.4.5.4 Strategic initiatives
8.4.6 AbbVie Inc.
8.4.6.1 Company overview
8.4.6.2 Product benchmarking
8.4.6.3 Strategic initiatives
8.4.7 GALDERMA LABORATORIES, L.P.
8.4.7.1 Company overview
8.4.7.2 Financial performance
8.4.7.3 Product benchmarking
8.4.7.4 Strategic initiatives
8.4.8 Dermira, Inc. (Eli Lilly and Company)
8.4.8.1 Company overview
8.4.8.2 Financial performance
8.4.8.3 Product benchmarking
8.4.8.4 Strategic initiatives
8.4.9 Novartis AG
8.4.9.1 Company overview
8.4.9.2 Financial performance
8.4.9.3 Product benchmarking
8.4.9.4 Strategic initiatives
8.4.10 Incyte Corporation
8.4.10.1 Company overview
8.4.10.2 Financial performance
8.4.10.3 Product benchmarking
8.4.10.4 Strategic initiatives
LIST OF TABLES
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 North America Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 4 North America Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 5 North America Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 6 U.S. Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 7 U.S. Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 8 Canada Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 9 Canada Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 10 Europe Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 11 Europe Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 12 Europe Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 13 U.K. Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 14 U.K. Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 15 Germany Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 16 Germany Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 17 France Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 18 France Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 19 Spain Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 20 Spain Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 21 Italy Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 22 Italy Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 23 Asia Pacific Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 24 Asia Pacific Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 25 Asia Pacific Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 26 Japan Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 27 Japan Atopic Dermatitis Drugs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 28 China Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 29 China Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 30 India Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 31 India Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 32 South Korea Atopic Dermatitis Drugs Market, By Drug Class2018 - 2030 (USD Million)
Table 33 South Korea Atopic Dermatitis Drugs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 34 Australia Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 35 Australia Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 36 Latin America Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 37 Latin America Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 38 Latin America Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 39 Brazil Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 40 Brazil Atopic Dermatitis Drugs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 41 Mexico Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 42 Mexico Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 43 Argentina Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 44 Argentina Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 45 Middle East & Africa Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 46 Middle East & Africa Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 47 Middle East & Africa Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 48 South Africa Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 49 South Africa Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 50 Saudi Arabia Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 51 Saudi Arabia Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 52 UAE Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 53 UAE Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 North America Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 4 North America Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 5 North America Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 6 U.S. Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 7 U.S. Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 8 Canada Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 9 Canada Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 10 Europe Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 11 Europe Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 12 Europe Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 13 U.K. Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 14 U.K. Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 15 Germany Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 16 Germany Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 17 France Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 18 France Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 19 Spain Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 20 Spain Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 21 Italy Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 22 Italy Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 23 Asia Pacific Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 24 Asia Pacific Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 25 Asia Pacific Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 26 Japan Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 27 Japan Atopic Dermatitis Drugs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 28 China Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 29 China Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 30 India Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 31 India Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 32 South Korea Atopic Dermatitis Drugs Market, By Drug Class2018 - 2030 (USD Million)
Table 33 South Korea Atopic Dermatitis Drugs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 34 Australia Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 35 Australia Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 36 Latin America Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 37 Latin America Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 38 Latin America Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 39 Brazil Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 40 Brazil Atopic Dermatitis Drugs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 41 Mexico Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 42 Mexico Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 43 Argentina Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 44 Argentina Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 45 Middle East & Africa Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 46 Middle East & Africa Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 47 Middle East & Africa Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 48 South Africa Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 49 South Africa Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 50 Saudi Arabia Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 51 Saudi Arabia Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 52 UAE Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 53 UAE Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Atopic dermatitis drugs market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Atopic dermatitis drugs market snapshot
Fig. 10 Atopic dermatitis drugs market driver impact
Fig. 11 Atopic dermatitis drugs market restraint impact
Fig. 12 Penetration and growth prospect mapping
Fig. 13 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 14 Porter’s five forces analysis
Fig. 15 Ansoff matrix
Fig. 16 Atopic dermatitis drugs market: Drug class outlook and key takeaways
Fig. 17 Atopic dermatitis drugs market: Drug class movement analysis
Fig. 18 Drug class segment dashboard
Fig. 19 Corticosteroids atopic dermatitis drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Calcineurin inhibitors atopic dermatitis drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 PDE4 inhibitors atopic dermatitis drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Biologics atopic dermatitis drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Others atopic dermatitis drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Atopic dermatitis drugs market: Route of administration outlook and key takeaways
Fig. 25 Atopic dermatitis drugs market: Route of administration analysis
Fig. 26 Route of administration dashboard
Fig. 27 Topical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Oral infections market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Atopic dermatitis drugs market: regional outlook and key takeaways
Fig. 31 Regional outlook, 2021 & 2030 (USD Million)
Fig. 32 Regional market dashboard
Fig. 33 North America
Fig. 34 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 U.S.
Fig. 36 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Canada
Fig. 38 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Europe
Fig. 40 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Germany
Fig. 42 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 U.K.
Fig. 44 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Spain
Fig. 46 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 France
Fig. 48 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Italy
Fig. 50 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Asia Pacific
Fig. 52 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Japan
Fig. 54 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 China
Fig. 56 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 India
Fig. 58 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 South Korea
Fig. 60 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Australia
Fig. 62 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Latin America
Fig. 64 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Brazil
Fig. 66 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Mexico
Fig. 68 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Argentina
Fig. 70 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Middle East & Africa
Fig. 72 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 South Africa
Fig. 74 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 UAE
Fig. 76 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 Saudi Arabia
Fig. 78 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Participant categorization
Fig. 80 Strategy mapping
Fig. 81 Strategic framework
Fig. 82 Company market share analysis
Fig. 1 Atopic dermatitis drugs market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Atopic dermatitis drugs market snapshot
Fig. 10 Atopic dermatitis drugs market driver impact
Fig. 11 Atopic dermatitis drugs market restraint impact
Fig. 12 Penetration and growth prospect mapping
Fig. 13 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 14 Porter’s five forces analysis
Fig. 15 Ansoff matrix
Fig. 16 Atopic dermatitis drugs market: Drug class outlook and key takeaways
Fig. 17 Atopic dermatitis drugs market: Drug class movement analysis
Fig. 18 Drug class segment dashboard
Fig. 19 Corticosteroids atopic dermatitis drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Calcineurin inhibitors atopic dermatitis drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 PDE4 inhibitors atopic dermatitis drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Biologics atopic dermatitis drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Others atopic dermatitis drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Atopic dermatitis drugs market: Route of administration outlook and key takeaways
Fig. 25 Atopic dermatitis drugs market: Route of administration analysis
Fig. 26 Route of administration dashboard
Fig. 27 Topical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Oral infections market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Atopic dermatitis drugs market: regional outlook and key takeaways
Fig. 31 Regional outlook, 2021 & 2030 (USD Million)
Fig. 32 Regional market dashboard
Fig. 33 North America
Fig. 34 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 U.S.
Fig. 36 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Canada
Fig. 38 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Europe
Fig. 40 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Germany
Fig. 42 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 U.K.
Fig. 44 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Spain
Fig. 46 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 France
Fig. 48 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Italy
Fig. 50 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Asia Pacific
Fig. 52 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Japan
Fig. 54 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 China
Fig. 56 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 India
Fig. 58 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 South Korea
Fig. 60 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Australia
Fig. 62 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Latin America
Fig. 64 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Brazil
Fig. 66 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Mexico
Fig. 68 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Argentina
Fig. 70 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Middle East & Africa
Fig. 72 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 South Africa
Fig. 74 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 UAE
Fig. 76 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 Saudi Arabia
Fig. 78 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Participant categorization
Fig. 80 Strategy mapping
Fig. 81 Strategic framework
Fig. 82 Company market share analysis
